Date | Price Target | Rating | Analyst |
---|---|---|---|
9/3/2024 | $35.00 | Outperform | Leerink Partners |
7/22/2024 | $24.00 | Hold → Buy | Jefferies |
7/18/2024 | $40.00 → $20.00 | Overweight → Neutral | JP Morgan |
7/10/2024 | $55.00 → $25.00 | Buy → Hold | Deutsche Bank |
6/27/2024 | Outperform → Peer Perform | Wolfe Research | |
6/25/2024 | Buy → Neutral | Guggenheim | |
6/3/2024 | $24.00 | Hold | Jefferies |
5/1/2024 | $57.00 → $32.00 | Buy → Hold | TD Cowen |
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer
Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an
Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar
PLEASANTON, Calif. , Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily driven by stronger contributions from consumables.Began shipping Xenium Prime 5K, which measures 5,000 genes and features an enhanced chemistry to deliver excellent per-gene sensitivity, improved specificity and spatial fidelity, and integrated m
PLEASANTON, Calif., July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the second quarter ended June 30, 2024 after market close on Thursday, August 8, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
PLEASANTON, Calif., April 30, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Revenue was $141.0 million for the first quarter, a 5% increase over the corresponding period of 2023, driven by Spatial revenue.Shipped Visium HD Spatial Gene Expression, enabling whole transcriptome spatial discovery at single cell-scale resolution.Shipped two major new Chromium products powered by GEM-X, the next generation of the company's leading singl
PLEASANTON, Calif., Oct. 1, 2024 /PRNewswire/ -- At the Human Cell Atlas General Meeting held September 29-30 in Milan, Italy, 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, shared new details about its upcoming product roadmap and its ongoing strategy to democratize access to single cell analysis. During its Foundational Sponsor talk in the Sept. 29 Technology Showcase, 10x Genomics announced an imminent plan to deliver "single cell for a single cent." Through a series of new products and configurations expected to launch this quarter, 10x Genom
In the September 9 cover article of Cancer Cell, researchers integrated 10x single cell and spatial technologies to identify a mechanism of glioblastoma recurrence in mice and develop a promising potential therapeutic approach. PLEASANTON, Calif., Sept. 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that its Chromium Single Cell Gene Expression and Xenium In Situ platforms were used in a publication – featured on the cover of Cancer Cell – that sheds light on the role of fibrotic scars in glioblastoma treatment recurrence. The study, led by researchers in the laboratory of Professor Johanna Joyce (University of Lausanne,
PLEASANTON, Calif., Sept. 3, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced the launch of Chromium Xo, a new addition to its fleet of Chromium single cell instruments. Designed to meet the needs of researchers who desire high-quality data on limited budgets, Chromium Xo offers an affordable entry point into routine, high-performance single cell analysis. "Chromium Xo is the latest in a series of 10x innovations intended to democratize single cell analysis because we never want researchers to have to settle for
10-Q - 10x Genomics, Inc. (0001770787) (Filer)
8-K - 10x Genomics, Inc. (0001770787) (Filer)
8-K - 10x Genomics, Inc. (0001770787) (Filer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and lowers the price target from $50 to $32.
Jefferies analyst Tycho Peterson upgrades 10x Genomics (NASDAQ:TXG) from Hold to Buy and maintains the price target from $24 to $24.
Leerink Partners initiated coverage of 10x Genomics with a rating of Outperform and set a new price target of $35.00
Jefferies upgraded 10x Genomics from Hold to Buy and set a new price target of $24.00
JP Morgan downgraded 10x Genomics from Overweight to Neutral and set a new price target of $20.00 from $40.00 previously